Century Therapeutics is a clinical-stage biotech developing allogeneic, off-the-shelf cell therapies for autoimmune diseases and type 1 diabetes (T1D). The company's platform is built on induced pluripotent stem cells (iPSCs) — stem cells that can self-renew and be banked indefinitely — allowing Century to manufacture therapies at scale in advance, unlike autologous approaches where cells must be collected, engineered, and returned to each individual patient. Century's proprietary Allo-Evasion engineering is designed to make its iPSC-derived cells resistant to host immune rejection, enabling cell persistence and potentially allowing repeat dosing without the toxic lymphodepleting chemotherapy (LDC) required before currently approved CAR-T therapies. Century's lead program, CNTY-101, is a CAR-iNK (natural killer) cell therapy targeting CD19+ B cells in autoimmune diseases like lupus and inflammatory myopathy, currently in a Phase 1/2 investigator-sponsored trial in Germany. CNTY-308, a CD19-targeted CAR-iT (T cell) therapy, and CNTY-813, an iPSC-derived beta islet cell therapy for T1D designed to restore insulin production without immunosuppression, are both in IND-enabling studies targeting a 2026 clinical start. Century operates its own 53,000 sq. ft. manufacturing facility in Branchburg, NJ. The company is pre-revenue and funds operations through equity raises, though Century has signaled openness to licensing or partnering individual pipeline assets, including an existing option agreement with Bayer covering future iNK cell programs.